NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)
CAPS Rating:
A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.
A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.
Recs
A major drug for short bowel syndrome. Although there are only about 15,000 patients in the US with this affliction-revenue production will be significant enough to warrant a takeover bid by a major pharma.